Han 2006a.
Methods |
|
|
Participants |
|
|
Interventions | Treatment group
Control group
All participants were allowed 30 mg ketorolac IM injections on demand. |
|
Outcomes |
|
|
Funding sources | None stated. | |
Declarations of interest | None stated. | |
Notes | Only English abstract available for judgement. | |
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | No quotes available. Comment: randomisation stated but no information on method used was available; therefore risk of selection bias was considered to be unclear. |
Allocation concealment (selection bias) | Unclear risk | No quotes available. Insufficient information to permit judgement. Comment: Owing to insufficient information, allocation concealment was considered to have unclear risk of bias. |
Blinding of participants and personnel (performance bias) All outcomes | Unclear risk | No quotes available. No blinding described. Comment: Owing to insufficient information, risk of performance bias was considered to be unclear. |
Blinding of outcome assessment (detection bias) All outcomes | Unclear risk | No quotes available. No blinding of outcome assessments described. Comment: Owing to insufficient information, risk of detection bias was considered to be unclear. |
Incomplete outcome data (attrition bias) All outcomes | Unclear risk | No quotes available. Comment: Losses to follow‐up were not clearly described; therefore risk of attrition bias was considered to be unclear. |
Selective reporting (reporting bias) | Unclear risk | No quotes available. Comment: Owing to insufficient information to permit judgement, risk of reporting bias was considered to be unclear. |
Other bias | Unclear risk | No quotes available. Comment: Owing to insufficient information to permit judgement, risk of other sources of bias was considered to be unclear. |